Adalimumab biobetter (Xencor/Zenas Biopharma)

N/A

Report date: 2025/01/02 16:12:02

Base Information

Drug NameAdalimumab biobetter (Xencor/Zenas Biopharma)
Drug Alias NameXmAb-6755ZB-002Xtend-TNF
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsAutoimmune Diseases of the Nervous SystemArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesXencor IncZenas BioPharma Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases of the Nervous SystemArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A